Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Tamoxifen 'boosts long-term breast cancer survival'

  • Comment

Breast cancer patients who are treated with tamoxifen have an improved chance of surviving for more than 10 years after starting the treatment, research suggests.

The study monitored long-term survival rates among more than 20,000 women with breast cancer.

Giving patients an early course of tamoxifen reduced their risk of dying by a third over a 15-year period and “substantially reduced” death rates well beyond 10 years, the findings showed.

Tamoxifen treats hormone sensitive (ER-positive) cancers by binding to molecular receptors on the tumour to prevent oestrogen stimulating growth.

The latest findings suggest that in many cases, the treatment may prevent the recurrence of breast cancer after several years.

Dr Christina Davies, a member of the international research team from Oxford University, said: “This study now shows that tamoxifen produces really long-term protection.

“For ER-positive disease, tamoxifen reduces 15-year breast cancer mortality by at least a third, whether or not chemotherapy has been given.”


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs